German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Since 2020, clinicians can prescribe – and SHI funds will reimburse – medical apps and digital health treatments, the so-called “DiGAs”. The BfArM assesses these DiGAs
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,
On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with
Despite strong opposition and critique raised by almost all stakeholders, the draft law on the financial stabilization of statutory health insurance (GKV-FinStG),
Following on from the EU regulation for medical devices (MDR) that came into force over one year ago, this week I am
Recently, I wrote about the planned reforms that the German Health Minister, Karl Lauterbach, wants to introduce with the act to stabilise
On 16 Aug 2019, the GSAV came into force. This new law also included legislation with the aim to increase the market
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
Hello! In this week’s post, I am describing the G-BA’s initiative to promote innovation in the German health care system and clinical
Recently, I have written about RWE collection, that can be mandated by the G-BA as part of their benefit assessment. Now, the